🇺🇸 INSULIN SUSP ISOPHANE RECOMBINANT HUMAN in United States

10 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Hypoglycaemic Coma — 2 reports (20%)
  2. Arthralgia — 1 report (10%)
  3. Death — 1 report (10%)
  4. Fall — 1 report (10%)
  5. Impaired Healing — 1 report (10%)
  6. Muscular Weakness — 1 report (10%)
  7. Sleep Apnoea Syndrome — 1 report (10%)
  8. Upper Limb Fracture — 1 report (10%)
  9. Vitreous Haemorrhage — 1 report (10%)

Source database →

INSULIN SUSP ISOPHANE RECOMBINANT HUMAN in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is INSULIN SUSP ISOPHANE RECOMBINANT HUMAN approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for INSULIN SUSP ISOPHANE RECOMBINANT HUMAN in United States?

Marketing authorisation holder not available in our data.